Achieving deep responses in previously treated CLL patients
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele
MRD testing will be a part of future AML clinical trials
Acute leukemias: is MRD already a surrogate for survival?
Adriano Venditti et al.
The importance of blinatumomab and inotuzumab ozogamicin in treating ALL